ARTICLE | Clinical News
Taspoglutide: Phase III data
December 21, 2009 8:00 AM UTC
The double-blind, international Phase III T-emerge 7 trial in 305 obese patients with Type II diabetes showed that subcutaneous weekly taspoglutide as an add-on to metformin met the primary endpoint o...